801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOral Medications

Glibenclamide Tablets Glyburide Tablets 2.5mg, 5mg Oral Medications

Glibenclamide Tablets Glyburide Tablets 2.5mg, 5mg Oral Medications

Glibenclamide Tablets Glyburide Tablets 2.5mg, 5mg Oral Medications

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 2.5mg, 5mg

Payment & Shipping Terms:

Minimum Order Quantity: Five million tablets
Price: Negotiation
Packaging Details: 10’s/box
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: One million pills per day
Contact Now
Detailed Product Description
Product: Glibenclamide Tablets Glyburide Tablets Specification: 2.5mg, 5mg
Standard: BP, USP Packing: 10’s/box

Glibenclamide Tablets Glyburide Tablets 2.5mg, 5mg Oral Medications

 

Product : Glibenclamide Tablets Glyburide Tablets

Specification : 2.5mg, 5mg

Standard : BP, USP

Packing : 10’s/box

 

Description :

Glibenclamide / Glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glibenclamide / Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide’s hypoglycemic effect is thought to be clinically unimportant. Glibenclamide / Glyburide metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m2.

 

Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.

 

Pharmacodynamics

Glibenclamide / Glyburide, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glibenclamide / glyburide produces a mild diuresis by enhancement of renal free water clearance. Glibenclamide / Glyburide is twice as potent as the related second-generation agent glipizide.

 

Mechanism of action

Sulfonylureas such as glyburide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)